2012 SABCS Public All Photos

$San Antonio, TX - SABCS 2012 San Antonio Breast Cancer Symposium: JM Balko discusses S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease during the Press Conference at the 2012 San Antonio Breast Cancer Symposium here today, Thursday December 6, 2012. Over 9,000 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Date: Thursday December 6, 2012 Photo by © SABCS/Todd Buchanan 2012 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154.$

187 / 280

San Antonio, TX - SABCS 2012 San Antonio Breast Cancer Symposium: JM Balko discusses S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease during the Press Conference at the 2012 San Antonio Breast Cancer Symposium here today, Thursday December 6, 2012. Over 9,000 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Date: Thursday December 6, 2012 Photo by © SABCS/Todd Buchanan 2012 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154.

Balko JM